Custom Search

Our Products · On-Line Store

HerpesVulvitis250.jpg (26798 bytes)

herpes250.jpg (15852 bytes)

 

 

Herpes Vulvitis

A tingling or itching sensation precedes the development of painful blisters on both sides of the vulva in acute herpes infection. The blisters then break open, releasing clear fluid, and form shallow ulcers, filled with grayish material. The ulcers then crust over and when the crusts fall off, the underlying skin looks normal. The process takes 7-10 days.

During the ulcerative stage, the pain may be so intense as to require narcotic analgesia. Urinating during this time can be extremely painful due to the hot, salty urine coming in contact with the open sores on the vulva. The pain may be so intense as to require such measures as urinating into a sitz bath or even placement of an indwelling urinary catheter (Foley).

The diagnosis is made by the typical appearance and may be confirmed with a herpes culture.

Although this lesion resolves spontaneously, re-occurrences are common.

Preferred treatment (CDC) for an initial outbreak is:

  • Acyclovir 400 mg orally three times a day for 7-10 days, OR
  • Acyclovir 200 mg orally five times a day for 7-10 days, OR
  • Famciclovir 250 mg orally three times a day for 7-10 days, OR
  • Valacyclovir 1 g orally twice a day for 7-10 days.

Preferred treatment (CDC) for a recurrence is:

  • Acyclovir 400 mg orally three times a day for 5 days, OR
  • Acyclovir 200 mg orally five times a day for 5 days, OR
  • Acyclovir 800 mg orally twice a day for 5 days, OR
  • Famciclovir 125 mg orally twice a day for 5 days, OR
  • Valacyclovir 500 mg orally twice a day for 5 days.

Some individuals have frequent recurrences, as often as every several weeks. For these women, "suppressive therapy" can be very helpful. Suppressive therapy involves taking relatively low doses of anti-viral medication daily, in order to keep the virus from causing such frequent attacks. Suggested regimens (CDC) for suppressive therapy include:

  • Acyclovir 400 mg orally twice a day, OR
  • Famciclovir 250 mg orally twice a day, OR
  • Valacyclovir 250 mg orally twice a day, OR
  • Valacyclovir 500 mg orally once a day, OR
  • Valacyclovir 1,000 mg orally once a day.

Another component of a herpes outbreak can be a bacterial superinfection. During the ulcerative stage, skin bacteria (strep, staph, coliforms) can attack the exposed ulcers, causing a bacterial infection of the ulcer. This is particularly true of large or multiple, confluent ulcers. These women may benefit (faster recovery and less pain) by the use of antibiotics such as amoxicillin, any cephalosporin or erythromycin, even though those drugs will have no effect on the course of the viral component of the herpes.

CDC Treatment Guidelines

Note to readers from the Brookside Associates:
Although this page faithfully reproduces the original Operational Medicine 2001, there are  newer CDC Treatment Guidelines (2006) available here.

 

Note to readers from the Brookside Associates:
Operational Obstetrics & Gynecology was released in 2000. There is a newer product, Military Obstetrics & Gynecology available here.

 

These videos are enhancements to the original Department of the Navy Publication

Pelvic Exam Video

Vulva Anatomy Video

Wet Mount Video

 

Bureau of Medicine and Surgery
Department of the Navy
2300 E Street NW
Washington, D.C
20372-5300

Operational Obstetrics & Gynecology - 2nd Edition
The Health Care of Women in Military Settings
CAPT Michael John Hughey, MC, USNR
NAVMEDPUB 6300-2C
January 1, 2000


 

 

Approved for public release; Distribution is unlimited.
The listing of any non-Federal product in this CD is not an endorsement of the product itself, but simply an acknowledgement of the source. 

Bureau of Medicine and Surgery
Department of the Navy
2300 E Street NW
Washington, D.C
20372-5300

Operational Medicine
 Health Care in Military Settings
CAPT Michael John Hughey, MC, USNR
NAVMED P-5139
  January 1, 2001

United States Special Operations Command
7701 Tampa Point Blvd.
MacDill AFB, Florida
33621-5323

*This web version is provided by The Brookside Associates Medical Education Division.  It contains original contents from the official US Navy NAVMED P-5139, but has been reformatted for web access and includes advertising and links that were not present in the original version. This web version has not been approved by the Department of the Navy or the Department of Defense. The presence of any advertising on these pages does not constitute an endorsement of that product or service by either the US Department of Defense or the Brookside Associates. The Brookside Associates is a private organization, not affiliated with the United States Department of Defense.

Contact Us  ·  Other Brookside Products

Operational Medicine 2001
Contents

 

 

 

Advertise on this site